Confluence Life Sciences raises $4mm through Series A round
Confluence Life Sciences Inc. (drug development for cancer and inflammation) has raised $4mm through its Series A round. DJF Mercury led and was joined by fellow new investors BioGenerator Accelerator Labs and Missouri Technology Corp., and seed investor the Helix Fund.
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.